{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T08:21:39Z","timestamp":1787559699385,"version":"build-2736575974"},"reference-count":178,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p>Acquired resistance to third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) presents a formidable challenge in the treatment of non-small cell lung cancer (NSCLC). Despite the remarkable efficacy of these agents, resistance inevitably develops, typically within approximately 10 months of treatment initiation. This review elucidates the multifaceted mechanisms driving this resistance, broadly categorized into on-target EGFR-dependent alterations and off-target EGFR-independent bypass pathway activations. On-target mechanisms include the emergence of tertiary EGFR mutations, most notably C797S, which disrupts TKI binding. Off-target mechanisms encompass the activation of alternative signaling pathways such as MET and HER2\/HER3 amplification, as well as histological transformations and complex changes within the tumor microenvironment. Furthermore, recent discoveries highlight the role of epigenetic dysregulation and metabolic reprogramming in fostering resistance. To counter this pervasive adaptability, advanced diagnostic methodologies, including liquid biopsy and high-resolution omics technologies, are crucial for real-time molecular profiling. The field is actively exploring emerging combination therapeutic strategies to circumvent these diverse resistance pathways, aiming to prolong clinical benefits and improve patient outcomes. The persistent emergence of resistance underscores that current targeted therapies, while revolutionary, are primarily disease-modifying rather than curative, necessitating continuous innovation to overcome the inherent biological challenge of tumor adaptability and heterogeneity.<\/jats:p>","DOI":"10.3389\/fcell.2026.1867246","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T07:59:10Z","timestamp":1787558350000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in understanding the mechanisms underlying acquired resistance to third-generation tyrosine kinase inhibitors in non-small cell lung cancer"],"prefix":"10.3389","volume":"14","author":[{"given":"Gu-Ha","family":"A-Lai","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Li","sequence":"additional","affiliation":[{"name":"Outpatient Department, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangzhi","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Sheng","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Yao","sequence":"additional","affiliation":[{"name":"Lung Cancer Center\/Lung Cancer Institute, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Dan","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e70036","DOI":"10.1002\/ddr.70036","article-title":"Orthoallosteric EGFR-TKIs: a new paradigm in NSCLC treatment strategy targeting the C797S mutation","volume":"86","author":"Ahmad","year":"2025","journal-title":"Drug Dev. Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1080\/14740338.2017.1300656","article-title":"EGFR TKI combination with immunotherapy in non-small cell lung cancer","volume":"16","author":"Ahn","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"key":"B3","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1200\/jco-24-01544","article-title":"TROPION-Lung01 trial investigators. Datopotamab deruxtecan Versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III TROPION-Lung01 study","volume":"43","author":"Ahn","year":"","journal-title":"J. Clin. Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1016\/j.jtho.2025.06.002","article-title":"A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLC","volume":"20","author":"Ahn","year":"","journal-title":"J. Thorac. Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"772","DOI":"10.3390\/genes16070772","article-title":"Management of MET-driven resistance to osimertinib in EGFR-mutant non-small cell lung cancer","volume":"16","author":"Angelopoulos","year":"2025","journal-title":"Genes (Basel)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.3390\/cancers17142388","article-title":"Co-Occurring genomic alterations in NSCLC: making order into a crowded list","volume":"17","author":"Attili","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/j.jtho.2025.06.012","article-title":"Molecular landscape and therapeutic strategies of lung cancer lineage plasticity","volume":"20","author":"Banerjee","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"71013","DOI":"10.18632\/oncotarget.11717","article-title":"Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer","volume":"7","author":"Bennett","year":"2016","journal-title":"Oncotarget"},{"key":"B9","doi-asserted-by":"publisher","first-page":"6936","DOI":"10.3390\/ijms23136936","article-title":"Acquired resistance to osimertinib in EGFR-Mutated non-small cell lung cancer: how do we overcome it?","volume":"23","author":"Bertoli","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"3894","DOI":"10.1158\/1078-0432.CCR-12-3696","article-title":"USP8 is a novel target for overcoming gefitinib resistance in lung cancer","volume":"19","author":"Byun","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e13824","DOI":"10.1111\/crj.13824","article-title":"The deubiquitinase USP22-Stabilized COL17A1 promotes lung adenocarcinoma progression","volume":"18","author":"Chen","year":"2024","journal-title":"Clin. Respir. J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e20726","DOI":"10.1200\/jco.2019.37.15_suppl.e20726","article-title":"Impact of next-generation sequencing on clinical outcomes in advanced EGFR-Mutant lung cancer patients after resistance to osimertinib","volume":"37","author":"Cheng","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e71302","DOI":"10.1002\/cam4.71302","article-title":"Third-generation EGFR-TKIs in T790M-Negative NSCLC after First\/second-generation EGFR-TKI failure: a retrospective study","volume":"14","author":"Cheng","year":"2025","journal-title":"Cancer Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/s41467-023-35961-y","article-title":"Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer","volume":"14","author":"Chmielecki","year":"","journal-title":"Nat. Commun."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/s41467-023-35962-x","article-title":"Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial","volume":"14","author":"Chmielecki","year":"","journal-title":"Nat. Commun."},{"key":"B16","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.bbrc.2006.12.035","article-title":"Snail is required for transforming growth factor-beta-induced epithelial-mesenchymal transition by activating PI3 Kinase\/Akt signal pathway","volume":"353","author":"Cho","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B17","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","article-title":"Kinase drug discovery 20 years after imatinib: progress and future directions","volume":"20","author":"Cohen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1038\/s41591-018-0177-5","article-title":"Classification and mutation prediction from non-small cell lung cancer histopathology images using deep learning","volume":"24","author":"Coudray","year":"2018","journal-title":"Nat. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1126\/science.1254721","article-title":"Patient-derived models of acquired resistance can identify effective drug combinations for cancer","volume":"346","author":"Crystal","year":"2014","journal-title":"Science"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e2502778122","DOI":"10.1073\/pnas.2502778122","article-title":"ZDHHC11-mediated AXL palmitoylation promotes osimertinib resistance in non-small-cell lung cancer","volume":"122","author":"Cui","year":"2025","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B21","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","article-title":"Cancer epigenetics: from mechanism to therapy","volume":"150","author":"Dawson","year":"2012","journal-title":"Cell"},{"key":"B22","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nrc3447","article-title":"Regulatory networks defining EMT during cancer initiation and progression","volume":"13","author":"De Craene","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s40265-018-0916-4","article-title":"Targeting EGFR in lung cancer: current standards and developments","volume":"78","author":"D\u00edaz-Serrano","year":"2018","journal-title":"Drugs"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1357913","DOI":"10.3389\/fphar.2024.1357913","article-title":"Furmonertinib for EGFR-mutant advanced non-small cell lung cancer: a glittering diamond in the rough of EGFR-TKI","volume":"15","author":"Ding","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"100103","DOI":"10.1016\/j.xinn.2021.100103","article-title":"Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors","volume":"2","author":"Du","year":"2021","journal-title":"Innov. (Camb)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"100125","DOI":"10.1016\/j.jlb.2023.100125","article-title":"BLU-945 monotherapy and combination with osimertinib in previously treated patients with advanced EGFR-mutant (EGFRm) NSCLC in phase 1\/2 SYMPHONY study","volume":"1","author":"Elamin","year":"2023","journal-title":"J. Liq. Biopsy"},{"key":"B27","doi-asserted-by":"publisher","first-page":"116161","DOI":"10.1016\/j.bcp.2024.116161","article-title":"Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines","volume":"228","author":"Eltayeb","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"100456","DOI":"10.1016\/j.jtocrr.2022.100456","article-title":"Overcoming resistance to osimertinib by T790M loss and C797S acquisition using gefitinib in a patient with EGFR-mutant NSCLC: a case report","volume":"4","author":"Enrico","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"key":"B29","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1158\/1078-0432.CCR-14-2789","article-title":"EGFR mutations and resistance to irreversible pyrimidine-based EGFR inhibitors","volume":"21","author":"Ercan","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.lungcan.2020.06.032","article-title":"Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: the phase II ATLANTIC study","volume":"147","author":"Garassino","year":"2020","journal-title":"Lung Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1038\/s41467-022-29292-7","article-title":"Knowledge graph-based recommendation framework identifies drivers of resistance in EGFR mutant non-small cell lung cancer","volume":"13","author":"Gogleva","year":"2022","journal-title":"Nat. Commun."},{"key":"B32","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.cell.2007.02.006","article-title":"Epigenetics: a landscape takes shape","volume":"128","author":"Goldberg","year":"2007","journal-title":"Cell"},{"key":"B33","doi-asserted-by":"publisher","first-page":"841","DOI":"10.3390\/cancers15030841","article-title":"Osimertinib resistance: molecular mechanisms and emerging treatment options","volume":"15","author":"Gomatou","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"5107","DOI":"10.1038\/s41598-025-89143-5","article-title":"Targeted cancer treatment using a novel EGFR-Specific Fc-fusion peptide based on GE11 peptide","volume":"15","author":"Hallaji","year":"2025","journal-title":"Sci. Rep."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1002\/1878-0261.12682","article-title":"Aspirin sensitizes osimertinib-resistant NSCLC cells in vitro and in vivo via bim-dependent apoptosis induction","volume":"14","author":"Han","year":"2020","journal-title":"Mol. Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1158\/2159-8290.cd-22-0586","article-title":"Osimertinib + savolitinib to overcome acquired MET-mediated resistance in epidermal growth factor receptor-mutated, MET-amplified non-small cell lung cancer: TATTON","volume":"13","author":"Hartmaier","year":"2023","journal-title":"Cancer Discov."},{"key":"B37","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1158\/1078-0432.ccr-21-3194","article-title":"A randomized phase II study comparing nivolumab with carboplatin-pemetrexed for EGFR-mutated NSCLC with resistance to EGFR tyrosine kinase inhibitors (WJOG8515L)","volume":"28","author":"Hayashi","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1200\/JCO.22.02186","article-title":"Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer: updated results from the phase III randomized ADAURA trial","volume":"41","author":"Herbst","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e03126","DOI":"10.1002\/cbdv.202503126","article-title":"Targeted protein degradation strategies for lung cancers: focusing on epidermal growth factor receptor","volume":"23","author":"Hou","year":"2026","journal-title":"Chem. Biodivers."},{"key":"B40","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.lungcan.2019.08.029","article-title":"Lung adenocarcinoma with sarcomatoid transformation after tyrosine kinase inhibitor treatment and chemotherapy","volume":"137","author":"Hsieh","year":"2019","journal-title":"Lung Cancer"},{"key":"B41","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.1038\/s41598-017-04258-8","article-title":"Blocking autophagy improves the anti-tumor activity of afatinib in lung adenocarcinoma with activating EGFR mutations in vitro and in vivo","volume":"7","author":"Hu","year":"2017","journal-title":"Sci. Rep."},{"key":"B42","doi-asserted-by":"publisher","first-page":"174346","DOI":"10.1016\/j.ejphar.2021.174346","article-title":"Inhibition of autophagy by YC-1 promotes gefitinib induced apoptosis by targeting FOXO1 in gefitinib-resistant NSCLC cells","volume":"908","author":"Hu","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1158\/0008-5472.can-23-0438","article-title":"ASCL1 drives tolerance to osimertinib in EGFR mutant lung cancer in permissive cellular contexts","volume":"84","author":"Hu","year":"2024","journal-title":"Cancer Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1186\/s12967-026-07940-6","article-title":"Single-cell profiling of tumor lineage plasticity and the immune microenvironment in transformed small cell lung cancer","volume":"24","author":"Huang","year":"2026","journal-title":"J. Transl. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"5031","DOI":"10.21873\/anticanres.16702","article-title":"Multi-gene liquid biopsy to detect resistance to first-line osimertinib in patients with EGFR-Mutated lung adenocarcinoma","volume":"43","author":"Ito","year":"2023","journal-title":"Anticancer Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"100481","DOI":"10.1016\/j.jtocrr.2023.100481","article-title":"Trastuzumab-emtansine and osimertinib combination therapy to target HER2 bypass track resistance in EGFR mutation-positive NSCLC","volume":"4","author":"Jebbink","year":"2023","journal-title":"JTO Clin. Res. Rep."},{"key":"B47","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/nature17960","article-title":"Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors","volume":"534","author":"Jia","year":"2016","journal-title":"Nature"},{"key":"B48","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.bbrc.2023.10.037","article-title":"Targeting MET endocytosis or degradation to overcome HGF-Induced gefitinib resistance in EGFR-Sensitive mutant lung adenocarcinoma","volume":"682","author":"Jiao","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.3390\/cancers17172791","article-title":"Cell death, molecular targeted therapies, and metabolic reprogramming in EGFR-mutant lung cancer","volume":"17","author":"Joshi","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B50","doi-asserted-by":"publisher","first-page":"4835","DOI":"10.1158\/0008-5472.can-20-2811","article-title":"Single-cell analyses reveal diverse mechanisms of resistance to EGFR tyrosine kinase inhibitors in lung cancer","volume":"81","author":"Kashima","year":"2021","journal-title":"Cancer Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/s43856-026-01546-1","article-title":"TAS3351 is a brain penetrable EGFR-TKI that overcomes T790M and C797S resistant mutations","volume":"6","author":"Kasuga","year":"2026","journal-title":"Commun. Med. (Lond)."},{"key":"B52","doi-asserted-by":"publisher","first-page":"4482","DOI":"10.1158\/0008-5472.CAN-18-0117","article-title":"Enhanced glycolysis supports cell survival in EGFR-mutant lung adenocarcinoma by inhibiting autophagy-mediated EGFR degradation","volume":"78","author":"Kim","year":"2018","journal-title":"Cancer Res."},{"key":"B53","doi-asserted-by":"publisher","first-page":"111736","DOI":"10.1016\/j.isci.2024.111736","article-title":"Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-Mutant non-small cell lung cancer","volume":"28","author":"Kim","year":"2025","journal-title":"iScience"},{"key":"B54","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2147\/LCTT.S147129","article-title":"Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature","volume":"8","author":"Klempner","year":"2017","journal-title":"Lung Cancer (Auckl)"},{"key":"B55","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.lungcan.2017.04.004","article-title":"Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC","volume":"108","author":"Knebel","year":"2017","journal-title":"Lung Cancer"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.3390\/pharmaceutics15061604","article-title":"The resistance to EGFR-TKIs in non-small cell lung cancer: from molecular mechanisms to clinical application of new therapeutic strategies","volume":"15","author":"Laface","year":"2023","journal-title":"Pharmaceutics"},{"key":"B57","doi-asserted-by":"publisher","first-page":"6195","DOI":"10.1158\/1078-0432.CCR-18-1542","article-title":"Landscape of EGFR-dependent and -Independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC","volume":"24","author":"Le","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"B58","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1200\/jco.24.00533","article-title":"A multicenter open-label randomized phase II study of osimertinib with and without ramucirumab in tyrosine kinase inhibitor-na\u00efve EGFR-mutant metastatic non-small cell lung cancer (RAMOSE trial)","volume":"43","author":"Le","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ejca.2021.01.052","article-title":"Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer","volume":"148","author":"Lee","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"B60","doi-asserted-by":"publisher","first-page":"799","DOI":"10.3349\/ymj.2022.63.9.799","article-title":"Lazertinib: on the way to its throne","volume":"63","author":"Lee","year":"2022","journal-title":"Yonsei Med. J."},{"key":"B61","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-Mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br. J. Cancer"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2018.01.005","article-title":"Interactions between EGFR and PD-1\/PD-L1 pathway: implications for treatment of NSCLC","volume":"418","author":"Li","year":"2018","journal-title":"Cancer Lett."},{"key":"B63","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1021\/acsmedchemlett.8b00564","article-title":"Discovery of potent and noncovalent reversible EGFR kinase inhibitors of EGFRL858R\/T790M\/C797S","volume":"10","author":"Li","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"B64","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12964-023-01082-8","article-title":"Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer","volume":"21","author":"Li","year":"","journal-title":"Cell Commun. Signal"},{"key":"B65","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s13402-023-00771-3","article-title":"The application of patient-derived organoid in the research of lung cancer","volume":"46","author":"Li","year":"","journal-title":"Cell Oncol. (Dordr)"},{"key":"B66","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41392-024-01981-3","article-title":"Mechanism exploration and model construction for small cell transformation in EGFR-mutant lung adenocarcinomas","volume":"9","author":"Li","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"key":"B67","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41419-024-06945-7","article-title":"PD-L1 induces autophagy and primary resistance to EGFR-TKIs in EGFR-mutant lung adenocarcinoma via the MAPK signaling pathway","volume":"15","author":"Li","year":"2024","journal-title":"Cell Death Dis."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.20892\/j.issn.2095-3941.2025.0153","article-title":"Research progress and challenges in the treatment of oncogene-addicted non-small cell lung cancer","volume":"22","author":"Li","year":"","journal-title":"Cancer Biol. Med."},{"key":"B69","doi-asserted-by":"publisher","first-page":"824","DOI":"10.21037\/tlcr-24-806","article-title":"Single cell RNA-Seq and bulk RNA-Seq analysis identifies MUC1 as a key gene for lung adenocarcinoma to neuroendocrine transformation","volume":"14","author":"Li","year":"","journal-title":"Transl. Lung Cancer Res."},{"key":"B70","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41698-025-01135-w","article-title":"GLMP promotes EGFR-TKI resistance by activating autophagy and RhoA pathway in non-small cell lung cancer","volume":"9","author":"Liang","year":"2025","journal-title":"NPJ Precis. Oncol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3390\/cancers17030459","article-title":"Optimizing osimertinib for NSCLC: targeting resistance and exploring combination therapeutics","volume":"17","author":"Liao","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B72","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.1158\/1078-0432.ccr-22-3901","article-title":"BBT-176, a novel fourth-generation tyrosine kinase inhibitor for Osimertinib-Resistant EGFR mutations in non-small cell lung cancer","volume":"29","author":"Lim","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"B73","doi-asserted-by":"publisher","first-page":"470","DOI":"10.3390\/biomedicines13020470","article-title":"Targeting the tumor microenvironment in EGFR-mutant lung cancer: opportunities and challenges","volume":"13","author":"Lim","year":"2025","journal-title":"Biomedicines"},{"key":"B74","doi-asserted-by":"publisher","first-page":"e71874","DOI":"10.1002\/cam4.71874","article-title":"Stanniocalcin 2-Induced autophagy confers resistance of lung cancer cells to EGFR inhibition via the ERK\/Beclin 1 signaling","volume":"15","author":"Liu","year":"2026","journal-title":"Cancer Med."},{"key":"B75","doi-asserted-by":"publisher","first-page":"3302","DOI":"10.1158\/0008-5472.CAN-11-3720","article-title":"Combined EGFR\/MET or EGFR\/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET","volume":"72","author":"Lu","year":"2012","journal-title":"Cancer Res."},{"key":"B76","doi-asserted-by":"publisher","first-page":"4655","DOI":"10.1158\/0008-5472.CAN-20-1192","article-title":"Hypoxia induces resistance to EGFR inhibitors in lung cancer cells via upregulation of FGFR1 and the MAPK pathway","volume":"80","author":"Lu","year":"2020","journal-title":"Cancer Res."},{"key":"B77","doi-asserted-by":"publisher","first-page":"CT008","DOI":"10.1158\/1538-7445.am2025-ct008","article-title":"Abstract CT008. First-in-human study of SYS6010, a novel EGFR targeting antibody drug conjugate (ADC) for patients with advanced solid tumors","volume":"85","author":"Lu","year":"2025","journal-title":"Cancer Res."},{"key":"B78","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s13046-022-02390-6","article-title":"Essential role for STAT3\/FOXM1\/ATG7 signaling-dependent autophagy in resistance to icotinib","volume":"41","author":"Lyu","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B79","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S1470-2045(24)00159-1","article-title":"BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study","volume":"25","author":"Ma","year":"2024","journal-title":"Lancet Oncol."},{"key":"B80","article-title":"Reprogramming of Osimertinib-Resistant EGFR-mutant NSCLC: the pyruvate-acetaldehyde-acetate pathway as a key driver of resistanc","author":"Maroni","year":"2024","journal-title":"biorxiv"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1101\/2025.06.27.661913","article-title":"Reprogramming of Osimertinib-Resistant EGFR-mutant NSCLC: the pyruvate-acetaldehyde-acetate pathway as a key driver of resistance","author":"Maroni","year":"","journal-title":"bioRxiv"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1101\/2025.07.04.663159","article-title":"Deciphering the role of acetate in metabolic adaptation and drug resistance in non-small cell lung cancer","author":"Maroni","year":"","journal-title":"bioRxiv"},{"key":"B83","doi-asserted-by":"publisher","first-page":"3488","DOI":"10.1200\/jco.2015.62.1342","article-title":"Systemic therapy for stage IV non-small-cell lung cancer: American society of clinical oncology clinical practice guideline update","volume":"33","author":"Masters","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.cell.2020.07.017","article-title":"Therapy-induced evolution of human lung cancer revealed by single-cell RNA sequencing","volume":"182","author":"Maynard","year":"2020","journal-title":"Cell"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.bbamcr.2006.10.001","article-title":"Roles of the Raf\/MEK\/ERK pathway in cell growth, malignant transformation and drug resistance","volume":"1773","author":"McCubrey","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"B86","doi-asserted-by":"publisher","first-page":"216587","DOI":"10.1016\/j.canlet.2023.216587","article-title":"USP7-mediated ER\u03b2 stabilization mitigates ROS accumulation and promotes osimertinib resistance by suppressing PRDX3 SUMOylation in non-small cell lung carcinoma","volume":"582","author":"Meng","year":"2024","journal-title":"Cancer Lett."},{"key":"B87","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.devcel.2021.02.010","article-title":"Autophagy and organelle homeostasis in cancer","volume":"56","author":"Miller","year":"2021","journal-title":"Dev. Cell"},{"key":"B88","doi-asserted-by":"publisher","first-page":"695","DOI":"10.21037\/tlcr.2016.12.02","article-title":"Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance","volume":"5","author":"Minari","year":"2016","journal-title":"Transl. Lung Cancer Res."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1111\/cas.70032","article-title":"Novel approach to overcome osimertinib resistance using bromodomain and extra-terminal domain inhibitors","volume":"116","author":"Miyashita","year":"2025","journal-title":"Cancer Sci."},{"key":"B90","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/nejmoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-Positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B91","doi-asserted-by":"publisher","first-page":"8506","DOI":"10.1200\/jco.2025.43.16_suppl.8506","article-title":"Patritumab deruxtecan (HER3-DXd) in resistant EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: the phase 3 HERTHENA-Lung02 study","volume":"43","author":"Mok","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.jtho.2020.11.028","article-title":"Beyond osimertinib: the development of third-generation EGFR tyrosine kinase inhibitors for advanced EGFR+ NSCLC","volume":"16","author":"Nagasaka","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"e70220","DOI":"10.1002\/ddr.70220","article-title":"Overcoming resistance in EGFR-mutant cancers: a comprehensive review of inhibitor evolution and SAR-based design","volume":"87","author":"Naykwadi","year":"2026","journal-title":"Drug Dev. Res."},{"key":"B94","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1158\/1078-0432.CCR-15-0560","article-title":"The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies","volume":"21","author":"Niederst","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"B95","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.jtho.2021.09.014","article-title":"IMpower150 final exploratory analyses for atezolizumab plus bevacizumab and chemotherapy in key NSCLC patient subgroups with EGFR mutations or metastases in the liver or brain","volume":"17","author":"Nogami","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1158\/0008-5472.CAN-16-2359","article-title":"Amplification of EGFR wild-type alleles in non-small cell lung cancer cells confers acquired resistance to mutation-selective EGFR tyrosine kinase inhibitors","volume":"77","author":"Nukaga","year":"2017","journal-title":"Cancer Res."},{"key":"B97","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3390\/ph13100273","article-title":"Epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC)","volume":"13","author":"O'Leary","year":"2020","journal-title":"Pharm. (Basel)"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1001\/jamaoncol.2018.2969","article-title":"Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-Positive lung cancer and acquired resistance to osimertinib","volume":"4","author":"Oxnard","year":"2018","journal-title":"JAMA Oncol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"viii741","DOI":"10.1093\/annonc\/mdy424.064","article-title":"LBA51Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study","volume":"29","author":"Papadimitrakopoulou","year":"2018","journal-title":"Ann. Oncol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s43018-021-00195-8","article-title":"Overcoming therapy resistance in EGFR-Mutant lung cancer","volume":"2","author":"Passaro","year":"2021","journal-title":"Nat. Cancer"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.3390\/ijms26041483","article-title":"Single-cell RNA sequencing in unraveling acquired resistance to EGFR-TKIs in non-small cell lung cancer: new perspectives","volume":"26","author":"Peng","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1056\/nejmoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B103","doi-asserted-by":"publisher","first-page":"S46","DOI":"10.1016\/j.jtho.2024.09.082","article-title":"OA16.05. Trastuzumab deruxtecan monotherapy in pretreated HER2-overexpressing nonsquamous non-small cell lung cancer: DESTINY-lung03 part 1","volume":"19","author":"Planchard","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"e2400331","DOI":"10.1200\/po.24.00331","article-title":"Safety and efficacy of osimertinib in patients with non-small-cell lung cancer and uncommon tumoral epidermal growth factor receptor mutations: a systematic review and single-arm meta-analysis","volume":"8","author":"Priantti","year":"2024","journal-title":"JCO Precis. Oncol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1111\/1759-7714.13906","article-title":"Targeting the EMT transcription factor snail overcomes resistance to osimertinib in EGFR-mutant non-small cell lung cancer","volume":"12","author":"Qin","year":"2021","journal-title":"Thorac. Cancer"},{"key":"B106","doi-asserted-by":"publisher","first-page":"803","DOI":"10.2147\/ott.s513879","article-title":"A rare histologic transformation from EGFR-positive lung adenocarcinoma to EGFR-negative squamous cell carcinoma after EGFR-TKIs resistance: a case report","volume":"18","author":"Qiu","year":"2025","journal-title":"Onco Targets Ther."},{"key":"B107","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41571-020-0340-z","article-title":"Lineage plasticity in cancer: a shared pathway of therapeutic resistance","volume":"17","author":"Quintanal-Villalonga","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"103040","DOI":"10.1016\/j.tice.2025.103040","article-title":"USP8-mediated CDH3 drives the malignant progression of lung adenocarcinoma by regulating ferroptosis","volume":"97","author":"Qv","year":"2025","journal-title":"Tissue Cell"},{"key":"B109","doi-asserted-by":"publisher","first-page":"5563746","DOI":"10.1155\/2021\/5563746","article-title":"Role of cytokines and chemokines in NSCLC immune navigation and proliferation","volume":"2021","author":"Ramachandran","year":"2021","journal-title":"Oxid. Med. Cell Longev."},{"key":"B110","doi-asserted-by":"publisher","first-page":"viii740","DOI":"10.1093\/annonc\/mdy424.063","article-title":"Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase iii flaura study","volume":"29","author":"Ramalingam","year":"2018","journal-title":"Ann. Oncol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1016\/j.jtho.2019.07.016","article-title":"EGFR-mutated lung cancers resistant to osimertinib through EGFR C797S respond to first-generation reversible EGFR inhibitors but eventually acquire EGFR T790M\/C797S in preclinical models and clinical samples","volume":"14","author":"Rangachari","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"102105","DOI":"10.1016\/j.ctrv.2020.102105","article-title":"EGFR exon 20 insertions in advanced non-small cell lung cancer: a new history begins","volume":"90","author":"Remon","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.jtho.2023.06.016","article-title":"Lazertinib Versus gefitinib tyrosine kinase inhibitors in treatment-na\u00edve patients with EGFR-mutated advanced NSCLC: analysis of the Asian subpopulation in LASER301","volume":"18","author":"Reungwetwattana","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.3390\/cancers14081931","article-title":"Acquired mechanisms of resistance to Osimertinib-The next challenge","volume":"14","author":"R\u00edos-Hoyo","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B115","doi-asserted-by":"publisher","first-page":"145453","DOI":"10.1016\/j.ijbiomac.2025.145453","article-title":"FL30: an epidermal growth factor kinase inhibitor overcoming T790M and C797S mutations through unique conformational modulation mechanism","volume":"319","author":"Romagnoli","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"100007","DOI":"10.1016\/j.xcrm.2020.100007","article-title":"Clonal evolution and heterogeneity of osimertinib acquired resistance mechanisms in EGFR mutant lung cancer","volume":"1","author":"Roper","year":"2020","journal-title":"Cell Rep. Med."},{"key":"B117","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/nrc.2017.84","article-title":"Understanding and targeting resistance mechanisms in NSCLC","volume":"17","author":"Rotow","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"B118","doi-asserted-by":"publisher","first-page":"17588359221130503","DOI":"10.1177\/17588359221130503","article-title":"Histologic transformation in lung cancer: when one door shuts, another opens","volume":"14","author":"Sato","year":"2022","journal-title":"Ther. Adv. Med. Oncol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.lungcan.2020.07.014","article-title":"Mechanisms of osimertinib resistance and emerging treatment options","volume":"147","author":"Schmid","year":"2020","journal-title":"Lung Cancer"},{"key":"B120","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1093\/annonc\/mdz077","article-title":"Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib","volume":"30","author":"Schoenfeld","year":"2019","journal-title":"Ann. Oncol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1158\/1078-0432.CCR-19-3563","article-title":"Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-Mutant lung cancer","volume":"26","author":"Schoenfeld","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"B122","doi-asserted-by":"publisher","first-page":"75ra26","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","volume":"3","author":"Sequist","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"B123","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3390\/cancers17020248","article-title":"Dynamic multilevel regulation of EGFR, KRAS, and MYC oncogenes: driving cancer cell proliferation through (Epi)Genetic and post-Transcriptional\/Translational pathways","volume":"17","author":"Seres","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B124","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1016\/j.celrep.2016.04.065","article-title":"Autophagy promotes focal adhesion disassembly and cell motility of metastatic tumor cells through the direct interaction of paxillin with LC3","volume":"15","author":"Sharifi","year":"2016","journal-title":"Cell Rep."},{"key":"B125","doi-asserted-by":"publisher","first-page":"188967","DOI":"10.1016\/j.bbcan.2023.188967","article-title":"20 years since the approval of first EGFR-TKI, gefitinib: insight and foresight","volume":"1878","author":"Singh","year":"2023","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"B126","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1021\/acsomega.3c06110","article-title":"4\u2033-Alkyl EGCG derivatives induce cytoprotective autophagy response by inhibiting EGFR in glioblastoma cells","volume":"9","author":"Singh","year":"2024","journal-title":"ACS Omega"},{"key":"B127","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1158\/2159-8290.cd-22-0620","article-title":"Integrative analysis of a large real-world cohort of small cell lung cancer identifies distinct genetic subtypes and insights into histologic transformation","volume":"13","author":"Sivakumar","year":"2023","journal-title":"Cancer Discov."},{"key":"B128","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.scib.2024.11.012","article-title":"SLC40A1+ macrophages contribute to the immunosuppressive tumor microenvironment in EGFR-mutated lung cancer","volume":"70","author":"Song","year":"2025","journal-title":"Sci. Bull. (Beijing)."},{"key":"B129","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/j.jtho.2023.08.017","article-title":"Central nervous system outcomes of lazertinib Versus gefitinib in EGFR-mutated advanced NSCLC: a LASER301 subset analysis","volume":"18","author":"Soo","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"B130","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/nejmoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B131","article-title":"Spatial dynamics of the tumor microenvironment in emerging resistance to targeted therapy in EGFR-Mutated NSCLC","year":"2025","journal-title":"bioRxiv"},{"key":"B132","doi-asserted-by":"publisher","first-page":"1467722","DOI":"10.3389\/fonc.2024.1467722","article-title":"A good response to furmonertinib fourth-line treatment of an advanced lung adenocarcinoma patient with EGFR exon20in and PIK3CA mutation: a case report and literature review","volume":"14","author":"Sun","year":"2024","journal-title":"Front. Oncol."},{"key":"B133","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41467-018-08074-0","article-title":"AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells","volume":"10","author":"Taniguchi","year":"2019","journal-title":"Nat. Commun."},{"key":"B134","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.1158\/1538-7445.am2022-3328","article-title":"Antitumor activity of BLU-945 and BLU-701 as single agents and in combination in EGFR L858R-driven models of NSCLC","volume":"82","author":"Tavera","year":"2022","journal-title":"Cancer Res."},{"key":"B135","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/s0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"key":"B136","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3892\/ol.2025.15121","article-title":"EGFR mutations in non-small cell lung cancer: classification, characteristics and resistance to third-generation EGFR-Tyrosine kinase inhibitors","volume":"30","author":"Tian","year":"2025","journal-title":"Oncol. Lett."},{"key":"B137","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1158\/2159-8290.CD-18-0903","article-title":"Single and dual targeting of mutant EGFR with an allosteric inhibitor","volume":"9","author":"To","year":"2019","journal-title":"Cancer Discov."},{"key":"B138","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3390\/curroncol32040191","article-title":"Resistance mutation profiles associated with current treatments for epidermal growth factor receptor-mutated non-small-cell lung cancer in the United States: a systematic literature review","volume":"32","author":"Vadagam","year":"2025","journal-title":"Curr. Oncol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1016\/j.jtho.2017.06.017","article-title":"Lung adenocarcinoma harboring EGFR T790M and in trans C797S responds to combination therapy of first- and third-generation EGFR TKIs and shifts allelic configuration at resistance","volume":"12","author":"Wang","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"B140","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13045-019-0759-9","article-title":"MET inhibitors for targeted therapy of EGFR TKI-Resistant lung cancer","volume":"12","author":"Wang","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"B141","doi-asserted-by":"publisher","first-page":"4607","DOI":"10.1038\/s41467-020-18442-4","article-title":"Transient IGF-1R inhibition combined with osimertinib eradicates AXL-Low expressing EGFR mutated lung cancer","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"key":"B142","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1002\/1878-0261.13112","article-title":"USP35 mitigates endoplasmic reticulum stress-induced apoptosis by stabilizing RRBP1 in non-small cell lung cancer","volume":"16","author":"Wang","year":"2022","journal-title":"Mol. Oncol."},{"key":"B143","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s10020-024-00934-4","article-title":"Utility of patient-derived xenografts to evaluate drug sensitivity and select optimal treatments for individual non-small-cell lung cancer patients","volume":"30","author":"Wang","year":"2024","journal-title":"Mol. Med."},{"key":"B144","doi-asserted-by":"publisher","first-page":"103044","DOI":"10.1016\/j.ctrv.2025.103044","article-title":"Transformation from EGFR-Mutant lung adenocarcinoma to small-cell lung cancer: from clonal evolution to lineage reprogramming","volume":"141","author":"Wang","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"B145","doi-asserted-by":"publisher","first-page":"2574526","DOI":"10.1080\/07853890.2025.2574526","article-title":"Precision navigation through the labyrinth: overcoming EGFR resistance in non-small cell lung cancer","volume":"57","author":"Wang","year":"2025","journal-title":"Ann. Med."},{"key":"B146","doi-asserted-by":"publisher","first-page":"10048","DOI":"10.1038\/s41467-025-66376-6","article-title":"Drug-tolerant persister cells in cancer: bridging the gaps between bench and bedside","volume":"16","author":"Wang","year":"2025","journal-title":"Nat. Commun."},{"key":"B147","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s12672-025-01974-w","article-title":"Modulation of almonertinib resistance in non-small cell lung cancer by cancer-associated fibroblasts through HK2-mediated glycolysis and SKP2 signaling","volume":"16","author":"Wei","year":"2025","journal-title":"Discov. Oncol."},{"key":"B148","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41388-018-0454-2","article-title":"Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI","volume":"38","author":"Weng","year":"2019","journal-title":"Oncogene"},{"key":"B149","doi-asserted-by":"publisher","first-page":"21438","DOI":"10.1021\/acs.jmedchem.4c02311","article-title":"Tilting the scales toward EGFR mutant selectivity: expanding the scope of bivalent Type V kinase inhibitors","volume":"67","author":"Wittlinger","year":"","journal-title":"J. Med. Chem."},{"key":"B150","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s42004-024-01108-3","article-title":"Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors","volume":"7","author":"Wittlinger","year":"","journal-title":"Commun. Chem."},{"key":"B151","doi-asserted-by":"publisher","first-page":"108831","DOI":"10.1016\/j.biopha.2019.108831","article-title":"Amplification of USP13 drives non-small cell lung cancer progression mediated by AKT\/MAPK signaling","volume":"114","author":"Wu","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"B152","doi-asserted-by":"publisher","first-page":"1738641","DOI":"10.3389\/fcell.2026.1738641","article-title":"Integrative single-cell and bulk RNA sequencing unravels the role of ACTN1 in promoting lung cancer with brain metastasis and epidermal growth factor receptor-tyrosine kinase inhibitor resistance","volume":"14","author":"Wu","year":"2026","journal-title":"Front. Cell Dev. Biol."},{"key":"B153","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.1002\/mco2.195","article-title":"Aldehyde dehydrogenase in solid tumors and other diseases: potential biomarkers and therapeutic targets","volume":"4","author":"Xia","year":"2020","journal-title":"MedComm"},{"key":"B154","doi-asserted-by":"publisher","first-page":"5485","DOI":"10.1007\/s13277-015-3215-7","article-title":"Posttranslational modifications of FOXO1 regulate epidermal growth factor receptor tyrosine kinase inhibitor resistance for non-small cell lung cancer cells","volume":"36","author":"Xu","year":"2015","journal-title":"Tumour Biol."},{"key":"B155","doi-asserted-by":"publisher","first-page":"e202501389","DOI":"10.1002\/chem.202501389","article-title":"Diethenyl sulfoximine (DESI) as an irreversible lysine-targeting warhead enables the design of covalent allosteric EGFR inhibitor","volume":"31","author":"Xu","year":"2025","journal-title":"Chemistry"},{"key":"B156","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.pccm.2023.10.005","article-title":"Small cell lung cancer transformations from non-small cell lung cancer: biological mechanism and clinical relevance","volume":"2","author":"Yang","year":"2024","journal-title":"Chin. Med. J. Pulm. Crit. Care Med."},{"key":"B157","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1158\/1078-0432.CCR-17-2310","article-title":"Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients","volume":"24","author":"Yang","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"B158","doi-asserted-by":"publisher","first-page":"1481244","DOI":"10.3389\/fonc.2025.1481244","article-title":"Almonertinib-induced interstitial lung disease in an NSCLC patient co-harboring EGFR Ex19del mutation and MET de novo amplification: a case report and literature review","volume":"15","author":"Yang","year":"2025","journal-title":"Front. Oncol."},{"key":"B159","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.semcancer.2022.03.006","article-title":"Small cell lung cancer transformation: from pathogenesis to treatment","volume":"86","author":"Yin","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"B160","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-Mutant lung cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"B161","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1001\/jamaoncol.2020.1260","article-title":"Effect of osimertinib and bevacizumab on progression-free survival for patients with metastatic EGFR-Mutant lung cancers: a phase 1\/2 single-group open-label trial","volume":"6","author":"Yu","year":"2020","journal-title":"JAMA Oncol."},{"key":"B162","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.2217\/fon-2022-1250","article-title":"HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC","volume":"19","author":"Yu","year":"","journal-title":"Future Oncol."},{"key":"B163","doi-asserted-by":"publisher","first-page":"5363","DOI":"10.1200\/jco.23.01476","article-title":"HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy","volume":"41","author":"Yu","year":"","journal-title":"J. Clin. Oncol."},{"key":"B164","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1158\/1538-7445.am2025-550","article-title":"Abstract 550: patient-Derived organoids as a screening platform to identify mechanisms of osimertinib resistance in non-small cell lung cancer","volume":"85","author":"Yu","year":"2025","journal-title":"Cancer Res."},{"key":"B165","doi-asserted-by":"publisher","first-page":"102557","DOI":"10.1016\/j.ctrv.2023.102557","article-title":"Acquired resistance mechanisms to osimertinib: the constant battle","volume":"116","author":"Zalaquett","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"B166","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1002\/1878-0261.12645","article-title":"Overcoming acquired resistance of EGFR-Mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol","volume":"14","author":"Zang","year":"2020","journal-title":"Mol. Oncol."},{"key":"B167","doi-asserted-by":"publisher","first-page":"1442237","DOI":"10.3389\/fonc.2024.1442237","article-title":"Targeting non-coding RNAs to overcome osimertinib resistance in EGFR-mutated non-small cell lung cancer","volume":"14","author":"Zeng","year":"2024","journal-title":"Front. Oncol."},{"key":"B168","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12943-018-0796-y","article-title":"Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities","volume":"17","author":"Zhang","year":"2018","journal-title":"Mol. Cancer"},{"key":"B169","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.canlet.2018.07.002","article-title":"USP22 promotes resistance to EGFR-TKIs by preventing ubiquitination-mediated EGFR degradation in EGFR-Mutant lung adenocarcinoma","volume":"433","author":"Zhang","year":"2018","journal-title":"Cancer Lett."},{"key":"B170","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.pccm.2024.08.002","article-title":"Overcoming EGFR-TKI resistance by targeting the tumor microenvironment","volume":"2","author":"Zhang","year":"2024","journal-title":"Chin. Med. J. Pulm. Crit. Care Med."},{"key":"B171","doi-asserted-by":"publisher","first-page":"e06950","DOI":"10.1002\/advs.202506950","article-title":"EGFR-TKIs induced DPP4 drives metabolic reprogramming of persister cells in lung cancer","volume":"12","author":"Zhang","year":"2025","journal-title":"Adv. Sci. (Weinh)"},{"key":"B172","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/s1470-2045(24)00379-6","article-title":"Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis","volume":"25","author":"Zhao","year":"2024","journal-title":"Lancet Oncol."},{"key":"B173","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41571-025-01085-z","article-title":"Navigating the landscape of EGFR TKI resistance in EGFR-Mutant NSCLC - mechanisms and evolving treatment approaches","volume":"23","author":"Zhao","year":"2026","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B174","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1016\/j.jtho.2019.04.020","article-title":"Durable clinical response of lung adenocarcinoma harboring EGFR 19Del\/T790M\/in trans-C797S to combination therapy of first- and third-generation EGFR tyrosine kinase inhibitors","volume":"14","author":"Zhou","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"B175","doi-asserted-by":"publisher","first-page":"5837","DOI":"10.1002\/ptr.7990","article-title":"Epigallocatechin gallate circumvents drug-induced resistance in non-small-cell lung cancer by modulating glucose metabolism and AMPK\/AKT\/MAPK axis","volume":"37","author":"Zhou","year":"2023","journal-title":"Phytother. Res."},{"key":"B176","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/s41419-024-07039-0","article-title":"PIM1 kinase promotes EMT-Associated osimertinib resistance via regulating GSK3\u03b2 signaling pathway in EGFR-Mutant non-small cell lung cancer","volume":"15","author":"Zhou","year":"2024","journal-title":"Cell Death Dis."},{"key":"B177","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.3389\/fonc.2019.01044","article-title":"EMT-mediated acquired EGFR-TKI resistance in NSCLC: mechanisms and strategies","volume":"9","author":"Zhu","year":"2019","journal-title":"Front. Oncol."},{"key":"B178","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3760\/cma.j.cn112147-20230815-00078","article-title":"Clinical analysis of lung adenocarcinoma with epidermal growth factor receptor mutation transformed into sarcoma","volume":"47","author":"Zhu","year":"2024","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2026.1867246\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T07:59:14Z","timestamp":1787558354000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2026.1867246\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":178,"alternative-id":["10.3389\/fcell.2026.1867246"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2026.1867246","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"article-number":"1867246"}}